Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
11
NCT06430671
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
Phase: Phase 1
Role: Collaborator
Start: Jun 18, 2024
Completion: Dec 31, 2025